![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer
CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer
![CMS_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/CMS_Logo.png?t=1580248734&width=430)
The Centers for Medicare and Medicaid Services (CMS) announced that it will begin covering FDA approved/cleared diagnostic tests that use next generation sequencing (NGS) to detect inherited ovarian and breast cancer.
“NGS tests provide the most comprehensive genetic analysis of a patient’s cancer because they enable simultaneous detection of multiple types of genetic alterations,” said CMS Administrator Seema Verma.
The NGS diagnostics provide clinical information that can help physicians develop a personalized cancer treatment plan for each patient.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct